《大行報告》里昂:調研二百名投資者大多數對醫療板塊正面 首選石藥及康哲藥業等
里昂發表研究報告指,邀請200名投資者進行調研,以便更好地了解最新的市場情緒。受訪者之中,大多數投資者仍然對中國醫療板塊發展持正面態度,並更有信心將大型製藥和生物技術視為首選領域。根據調查結果,創新藥領域是最受關注的投資主題,因為它們將進入一個新產品週期,並具有潛在的海外擴張能力,或有助於提升估值。
報告提到,大部分投資者認為,雖然內地醫藥反腐風暴可能令近期行業表現受壓,但其影響應會在明年逐步消失,整體產業需求將保持韌性。就產業增長方面,普遍受訪者預計2023及24年的增長將介乎5%至10%,而大多數人認為優質產業公司可在2023至25年期間維持10%至15%增長。
該行認為,藥物審評中心(CDE)加強藥物評估將鼓勵行業開發真正創新的產品。而持續政策利好,包括醫療保險支付能力的提高和新的國家醫保目錄更新規定,應繼續推動國內藥物創新。該行表示,在醫療板塊中首選大型製藥公司,包括石藥(01093.HK)、康哲藥業(00867.HK)、翰森製藥(03692.HK)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.